Investor Relations

Corporate Profile

RVL Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. We are currently commercializing Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelids, in adults. Upneeq is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.

Prior to November 22, 2023, RVL Pharmaceuticals, Inc. and its wholly-owned subsidiary RVL Pharmacy, LLC (together with RVL Pharmaceuticals, Inc. the “RVL US Operating Subsidiaries”) were indirectly owned by RVL Pharmaceuticals plc, an Irish public limited company with publicly traded equity securities.

On November 22, 2023, the RVL US Operating Subsidiaries successfully emerged from their Chapter 11 cases following the confirmation by the United States Bankruptcy Court for the District of Delaware of their Plan of Reorganization (“Plan”), which was confirmed by the court on November 20, 2023. Going forward, the RVL US Operating Subsidiaries are well-positioned to invest in UPNEEQ, drive their strategic initiatives, and continue to deliver high-quality, innovative ocular and aesthetic solutions for patients and healthcare partners.

Following the implementation of the Plan, the wind-down of RVL Pharmaceuticals plc, and its subsidiaries other than the RVL US Operating Subsidiaries has commenced. RVL Pharmaceuticals plc’s public equity is expected to be cancelled upon completion of its wind-down activities during 2024.